Schneider Electric to Buy All of India JV in €5.5 Billion Deal
The French industrial technology firm will pay €5.5 billion ($6.4 billion) in cash to gain full ownership of Schneider Electric India Pvt, according to a statement Wednesday. Bloomberg News reported earlier this month that Schneider Electric was in talks to buy the Temasek stake.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 minutes ago
- Business Wire
Tikehau Capital: Share Capital Reduction by Cancellation of Treasury Shares
PARIS--(BUSINESS WIRE)--Regulatory News: Tikehau Capital (Paris:TKO) cancelled today 1,145,144 treasury shares, representing 0.65% of the share capital, in accordance with the authorization granted by the General Meeting of 6 May 2024 in its 29 th resolution. The share capital now amounts to 2,102,974,080 euros divided into 175,247,840 shares and the number of exercisable voting rights amounts to 172,478,794. Following this cancellation of shares, Tikehau Capital directly owns 2,769,046 of its own shares (1.58% of the share capital). All the cancelled shares were repurchased under Tikehau Capital's share buyback programme pursuant to the authorisation given by the General Meeting of 19 May 2022, in its 17 th resolution, and by the General Meeting of 16 May 2023, in its 11 th resolution. A description of the share buyback programme (published in paragraph 8.3.4 of the Tikehau Capital Universal Registration Document filed with the French financial markets authority on 20 March 2025 under number D. 25-0123) is available on the company's website in the Regulated Information section ( ABOUT TIKEHAU CAPITAL Tikehau Capital is a global alternative asset management Group with €51.0 billion of assets under management (as of 30 June 2025). Tikehau Capital has developed a wide range of expertise across four asset classes (credit, real assets, private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Tikehau Capital is a founder-led team with a differentiated business model, a strong balance sheet, proprietary global deal flow and a track record of backing high quality companies and executives. Deeply rooted in the real economy, Tikehau Capital provides bespoke and innovative alternative financing solutions to companies it invests in and seeks to create long-term value for its investors, while generating positive impacts on society. Leveraging its strong equity base (€3.1 billion of shareholders' equity as of 30 June 2025), the Group invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 735 employees (as of 30 June 2025) across its 17 offices in Europe, the Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: For more information, please visit: DISCLAIMER This document does not constitute an offer of securities for sale or investment advisory services. It contains general information only and is not intended to provide general or specific investment advice. Past performance is not a reliable indicator of future earnings and profit, and targets are not guaranteed. Certain statements and forecasted data are based on current forecasts, prevailing market and economic conditions, estimates, projections and opinions of Tikehau Capital and/or its affiliates. Due to various risks and uncertainties, actual results may differ materially from those reflected or expected in such forward-looking statements or in any of the case studies or forecasts. All references to Tikehau Capital's advisory activities in the US or with respect to US persons relate to Tikehau Capital North America.
Yahoo
an hour ago
- Yahoo
Tottenham Ramp Up Efforts for €45M-Rated PSG Outcast Wanted by Man Utd, Newcastle
Randal Kolo Muani made a strong impression during his loan stint at Juventus, racking up 10 goal contributions in 19 appearances across all competitions. But with no agreement yet between Juventus and PSG, his future remains uncertain — and several Premier League clubs are beginning to show serious interest. According to Corriere dello Sport, Juventus have submitted an offer to Paris Saint-Germain for a paid loan worth €10 million. The proposal includes a purchase option that would become mandatory if Juventus secure Champions League qualification. PSG, however, are holding out for a guaranteed transfer clause in the €40 million to €45 million range. The French striker is also on the radar of Premier League sides, with Chelsea, Newcastle, and especially Manchester United closely monitoring his situation ahead of a potential summer move. Tottenham Hotspur step up efforts for PSG outcastFoot Mercato reported Thursday that Tottenham are still aiming to bolster their attack and have already identified Kolo Muani as a target. More importantly, they're prepared to offer PSG a straight transfer deal, something that the Parisian club would welcome. But they're not alone. The report adds that other top English sides are also in the mix. Manchester United and Newcastle are both searching for a long-term option up front, which could complicate matters for Juventus. The Italian club, still working to trim its squad and raise funds, may struggle to compete with the financial and competitive appeal of Kolo Muani's other suitors. Transfer insider Fabrizio Romano recently confirmed that Juventus remain in active discussions with PSG, with another round of talks set to continue as the two clubs work on the deal's structure.
Yahoo
2 hours ago
- Yahoo
Dupixent sales spur Sanofi growth, but profits fall short
Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported lower-than-expected profits after outlaying money to develop new treatments. Dupixent generated sales of €3.8bn ($4.35bn) for the company in the quarter, growing 21.1% over the same period in 2024. Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent's success pushed Sanofi's total net sales to €9.9bn, up 10% at constant exchange rate (CER). The French drugmaker said it expects annual sales growth in the high single-digits at constant currency rates, compared to a previous forecast of mid- to high-single-digit growth. In a conference call on 31 July, chief financial officer François-Xavier Roger said that whilst tariffs were not modelled into the guidance, little impact is expected on financials in 2025. Sanofi CEO Paul Hudson said: 'Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses.' Sanofi confirmed it hopes to complete a €5bn share buyback programme in 2025, adding that around 80% has been repurchased to date. However, despite progressing its ownership control, earnings per share rose 1.9% to €1.59, lower than the €1.65 analysts estimated. Shares in Sanofi fell 1% at market open to €84.70 on the Paris exchange following the Q2 report posting, despite the strong growth for Dupixent. The profit miss was primarily due to an increase in research and development (R&D) expenses. Sanofi invested €1.9bn into the department as it seeks new drugs and vaccines to succeed Dupixent, wary of its outlook becoming too reliant on sales for the product. The R&D spending represented a 17.7% jump compared to Q2 last year. Sanofi also looked beyond in-house development in efforts to bolster its pipeline – the pharma company has had a busy July in the acquisition space. In July, the drugmaker concluded its buyout of Blueprint Medicines for $9.1bn and agreed to acquire vaccine developer Vicebio for an upfront payment of $1.5bn. In addition, Sanofi bought Dren Bio's bispecific antibody for $1.9bn in March 2025 and made a push into Alzheimer's with a $470m deal for Vigil Neuroscience in May. Despite M&A buzz, Sanofi shares have declined this year in comparison to other big pharma companies. This has been primarily due to vaccine regulation uncertainty in the US. Alongside the company's pipeline diversification strategy, Duxipent looks set to supply a healthy financial outlook for Sanofi. Analysis by GlobalData forecasts sales of €23.8bn by 2031. This is based on rising uptake for the drug and further indications it's set to gain approval in. GlobalData analysts said Dupixent addressed a biologics gap in the COPD market at the time of approval. "Dupixent sales spur Sanofi growth, but profits fall short" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
